Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease - the IG-IBD LIVE study
Aliment Pharmacol Ther
.
2022 Aug;56(4):731-732.
doi: 10.1111/apt.16957.
Authors
Helen Lee
1
,
Nabeel Khan
1
2
Affiliations
1
Department of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
2
Department of Gastroenterology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA.
PMID:
35879894
DOI:
10.1111/apt.16957
No abstract available
Publication types
Editorial
Comment
MeSH terms
Aged
Antibodies, Monoclonal, Humanized / adverse effects
Cohort Studies
Humans
Inflammatory Bowel Diseases* / drug therapy
Middle Aged
Substances
Antibodies, Monoclonal, Humanized
vedolizumab